BILL ANDERSON was named CEO of Genentech, which is a member of the Roche Group, effective Jan. 1, 2017. He takes over from Ian T. Clark who retires at the end of 2016 after 14 years of service. Anderson, who is also the head of North American commercial operations, has served in a number of...
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
